Seung-Ah Yahng - Search Results

Year	Number of Results
2009	1
2010	2
2011	7
2012	8
2013	19
2014	14
2015	8
2016	3
2017	2
2018	6
2019	2
2020	9
2021	8
2022	7
2023	5
2024	3
2025	6
2026	3

1

Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108.

Choi S, Byun JM, Oh SE, Han J, Jung S, Han S, Shin SH, Yahng SA, Jeon YW, Li J, Park SS, Suzuki K, Min CK; Catholic Research Network for Multiple Myeloma. Choi S, et al. Among authors: yahng sa. Blood Cancer J. 2026 Mar 31;16(1):52. doi: 10.1038/s41408-026-01475-1. Blood Cancer J. 2026. PMID: 41916953 Free PMC article.

2

Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study.

Lee JY, Choi S, Jung S, Park SS, Kim JS, Shin SH, Jeon YW, Yahng SA, Lee JJ, Kim HJ, Lee GW, Eom HS, Kim MK, Kim Y, Kwon J, Min CK; Korean Multiple Myeloma Working Party (KMMWP). Lee JY, et al. Among authors: yahng sa. Ann Hematol. 2026 Mar 23;105(4):193. doi: 10.1007/s00277-026-06849-w. Ann Hematol. 2026. PMID: 41866558 Free PMC article.

3

Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma.

Kim TY, Min KI, Min GJ, Jeon Y, Yahng SA, Cho SG, Eom KS. Kim TY, et al. Among authors: yahng sa. Cytotherapy. 2026 Apr;28(4):102028. doi: 10.1016/j.jcyt.2025.102028. Epub 2025 Dec 2. Cytotherapy. 2026. PMID: 41689916

4

Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study.

Oh S, Park SS, Lee JY, Yoon JH, Lee SE, Kim HJ, Shin SH, Jeon YW, Yahng SA, Jung J, Ahn A, Kim M, Min CK. Oh S, et al. Among authors: yahng sa. Blood Res. 2025 Oct 23;60(1):54. doi: 10.1007/s44313-025-00101-6. Blood Res. 2025. PMID: 41129059 Free PMC article.

5

Efficacy and safety of rituximab-based chemoimmunotherapy in adult patients with Burkitt lymphoma in Korea.

Min GJ, Kim KY, Kim TY, Jeon YW, Kim BS, Yahng SA, Eom KS, Cho SG. Min GJ, et al. Among authors: yahng sa. Front Oncol. 2025 Jul 9;15:1614506. doi: 10.3389/fonc.2025.1614506. eCollection 2025. Front Oncol. 2025. PMID: 40703543 Free PMC article.

6

Prognostic Value of Very Early Interim FDG PET/CT After Single Cycle of Chemotherapy for 10-Year Survival in Diffuse Large B-Cell Lymphoma.

Han EJ, Park HL, Yahng SA, Min GJ, Choi BO, Park G, O JH, Cho SG; Catholic University Lymphoma Group. Han EJ, et al. Among authors: yahng sa. Cancers (Basel). 2025 Mar 8;17(6):926. doi: 10.3390/cancers17060926. Cancers (Basel). 2025. PMID: 40149263 Free PMC article.

7

Inferior Outcomes of Fludarabine-Cyclophosphamide-Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia.

Kim TY, Min GJ, Jeon YW, Yahng SA, Cho SG, Lee JM, Kim M, Eom KS. Kim TY, et al. Among authors: yahng sa. Biomedicines. 2025 Jan 14;13(1):194. doi: 10.3390/biomedicines13010194. Biomedicines. 2025. PMID: 39857777 Free PMC article.

8

Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study.

Choi S, Byun JM, Park SS, Han J, Oh S, Jung S, Park H, Han S, Lee JY, Koh Y, Jeon YW, Yahng SA, Shin SH, Yoon SS, Min CK. Choi S, et al. Among authors: yahng sa. Transplant Cell Ther. 2025 Feb;31(2):74.e1-74.e11. doi: 10.1016/j.jtct.2024.11.010. Epub 2024 Nov 26. Transplant Cell Ther. 2025. PMID: 39608453 Free article.

9

Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study.

Huh CY, Park SS, Lee JY, Min CK; Catholic Research Network for Multiple Myeloma (CAREMM-2002 study). Huh CY, et al. Blood Res. 2024 Jul 17;59(1):24. doi: 10.1007/s44313-024-00025-7. Blood Res. 2024. PMID: 39017764 Free PMC article. No abstract available.

10

Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.

Park S, Bang SY, Kwag D, Lee JH, Kim TY, Lee J, Min GJ, Park SS, Yahng SA, Jeon YW, Shin SH, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Park S, et al. Among authors: yahng sa. Bone Marrow Transplant. 2024 Jun;59(6):813-823. doi: 10.1038/s41409-024-02255-w. Epub 2024 Mar 4. Bone Marrow Transplant. 2024. PMID: 38438648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year